Langley Paul C
College of Pharmacy University of Minnesota.
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1629. eCollection 2019.
In a recent commentary in INNOVATIONS in Pharmacy, details were given on a recently released Chronic Pain Management Registry (CPMR). The CPMR was designed to provide a tracking and audit framework for evaluating claims made for therapy interventions in chronic pain management. At the same time, the CPMR was seen as a key element in monitoring physician and practice compliance with requirements for the prescribing of opioids and other scheduled substances. The purpose of the present commentary is to expand upon the role of the CPMR in the management of opioids in detailing the concordance of the CPMR data collection requirements with the latest recommendations of the American Society of Interventional Pain Physicians (ASIPP) for responsible, safe and effective opioid prescribing in chronic non-cancer pain. Given ongoing concerns with opioid misuse and abuse, the opioid epidemic, physician practices are at risk for what may be judged as poor therapy decisions in evaluating medical necessity and a failure to monitor effectively response to therapy. Adoption of a platform such as the CPMR may, through providing a comprehensive evidence base and tracking capability, support more effective prescribing decisions and adherence to therapy. At the same time, the ability to justify decisions through a CPMR documentation audit may not only alleviate physician concerns if their decisions are challenged but also lead to improved outcomes in the treatment of chronic pain.
在近期发表于《药学创新》的一篇评论中，详细介绍了最近发布的慢性疼痛管理登记系统（CPMR）。CPMR旨在提供一个跟踪和审核框架，用于评估慢性疼痛管理中治疗干预措施的相关声明。同时，CPMR被视为监测医生及医疗机构是否符合阿片类药物和其他管制物质处方要求的关键要素。本评论的目的是在详述CPMR数据收集要求与美国介入性疼痛医师协会（ASIPP）关于慢性非癌性疼痛中负责任、安全且有效开具阿片类药物处方的最新建议的一致性时，进一步阐述CPMR在阿片类药物管理中的作用。鉴于对阿片类药物滥用和误用的持续担忧，即阿片类药物流行问题，医生在评估医疗必要性以及未能有效监测治疗反应时，可能面临被判定治疗决策不佳的风险。采用CPMR这样的平台，通过提供全面的证据基础和跟踪能力，可能支持更有效的处方决策和治疗依从性。同时，通过CPMR文件审核来证明决策合理性的能力，不仅在医生的决策受到质疑时可以减轻他们的担忧，还能改善慢性疼痛的治疗效果。
